Is higher lymphocyte count a potential strategy for preventing chronic kidney disease in patients receiving long-term dasatinib treatment?

BACKGROUND: Dasatinib, which is used to treat treating chronic myeloid leukemia, induces increases in blood lymphocytes during the treatment. In addition, neutrophil–lymphocyte count ratio (NLR) is associated with the related to development of chronic kidney disease (CKD). However, it has not been r...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakayama, Hirokazu, Iizuka, Hiromitsu, Kato, Toshiaki, Usuki, Kensuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Short Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872443/
https://www.ncbi.nlm.nih.gov/pubmed/36691104
http://dx.doi.org/10.1186/s40780-022-00270-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9872443/
https://www.ncbi.nlm.nih.gov/pubmed/36691104
http://dx.doi.org/10.1186/s40780-022-00270-x

Ejemplares similares